Bristol Myers Squibb (BMS) has significantly expanded its footprint in India, establishing Hyderabad as its largest operational center with approximately 3,000 employees. According to The Hindu BusinessLine, Cristian Massacesi, the company’s Executive Vice President and Chief Medical Officer, confirmed that this site is fully integrated into global development efforts. The workforce comprises roughly 1,300 individuals in development roles, supported by teams handling information technology, finance, and manufacturing. This structure allows project leaders in the United States to collaborate seamlessly with statisticians and clinical specialists based in Hyderabad.
The pharmaceutical giant is leveraging artificial intelligence to address the high failure rates and substantial costs inherent in drug discovery. Massacesi highlighted that more than 90 per cent of candidates entering clinical trials do not reach approval, with development timelines often spanning nine to thirteen years. The financial burden for a single drug can range from $800 million to $2 billion. To mitigate these challenges, BMS is employing data and language models to optimize trial designs and predict outcomes. The company has partnered with technology firms, including NVIDIA, and provides staff access to AI tools like Claude, which Massacesi uses for about 30 per cent of his tasks.
Beyond Hyderabad, BMS maintains critical operations in Bengaluru and Mumbai. The Bengaluru facility specializes in small-molecule research, including oral formulations, and is increasingly engaging with large molecules and antibodies. Mumbai hosts commercial and clinical teams responsible for identifying hospitals and academic institutions to enroll patients. Massacesi noted that the company currently oversees more than 40 clinical trials in India, with every new study assessed for local feasibility. The Mumbai-based operational group plays a pivotal role in connecting these trials with healthcare providers.
The company also relies on external partnerships to sustain its innovation pipeline. BMS collaborates with Syngene on research and development, including support for a clinical trial involving an immunology drug. Massacesi stated that the firm is open to further collaborations with entities whose innovations align with its strategic goals. The total workforce across Hyderabad, Bengaluru, and Mumbai stands at between 3,500 and 3,700 high-skilled professionals. Massacesi expressed confidence that the value brought by this investment, employment, and ecosystem would be recognized by stakeholders.
